Cutaneous wound healing
Régentis-Pharma develops medical devices able to decrease inflammatory reaction and to improve the quality of wound healing.
Based on more than 30 years of experience in matrikines (synthetic peptides derived from extracellular matrix and able to stimulate tissue regeneration), Regentis Pharma is the EU leader in discovery of synthetic peptides for tissue regeneration.
Regentis Pharma is a spin-off of Reims Champagne Ardennes University and the SFR-Cap Santé incorporated in 2008. Regentis Pharma is an innovative biotechnology company specializing in the development and marketing of medical treatments and devices related to tissue regeneration. The expertise of Regentis Pharma is the discovery of synthetic bifunctional peptides in tissue regeneration for cosmetic, medical device & pharmaceutical applications.
Regentis Pharma aims to collaborate with partners in order to develop together new medical devices. Regentis-Pharma’s business model is to license innovative bifunctional peptide to private partners, in the fields of dermo-cosmetics, medical devices, pathology treatments (periodontal diseases, severe burns or diabetic foot ulcers).
Régentis-Pharma develops medical devices able to decrease inflammatory reaction and to improve the quality of wound healing.
Our laboratory investigates a better efficacy for treatments of periodontal diseases: gingivitis and periodontitis.
Régentis-Pharma has developed an innovative anti-aging cosmetic product that has been the subject of clinical trials in humans.